Pyxis Oncology, Inc. (PYXS) Stock Score, Valuation & Financial Research

Pyxis Oncology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PYXS

Pyxis Oncology, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.79. These figures are a research snapshot, not a buy or sell recommendation.

What Pyxis Oncology, Inc. does

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Pyxis Oncology is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its oncology therapeutic pipeline.

Products and services

  • The company is developing a pipeline of oncology therapeutics, with its lead candidate being micvotabart pelidotin (MICVO), an antibody-drug conjugate currently in clinical trials for solid tumors, including head and neck squamous cell carcinoma.

Brands and product families

  • MICVO (micvotabart pelidotin) — Lead clinical-stage antibody-drug conjugate candidate. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its clinical trial drug candidates. Source

Business relationships and partnerships

  • Merck — A clinical collaboration for a Pyxis Oncology-sponsored study of micvotabart pelidotin in combination with Merck’s anti-PD-(L)1 therapy, KEYTRUDA (pembrolizumab). Source

Business strengths to evaluate

  • Clinical data for lead candidate MICVO in R/M HNSCC Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PYXS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.79
Market capitalization:
113.41M (currency not supplied)
Revenue:
USD 11.04M
Net income:
USD -88.73M
Free cash flow:
USD -63.51M
Cash:
USD 18.86M
Total debt:
USD 17.83M
EPS:
USD -1.41

What stands out

  • Reported year-over-year revenue growth is -20.3%.
  • Free cash flow is USD -63.51M, negative for the stored period.
  • The balance sheet shows USD 18.86M of cash versus USD 17.83M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -575.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -803.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 1.02M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PYXS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving PYXS's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can PYXS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PYXS's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PYXS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PYXS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research PYXS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.